Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Oops, it doesn't like my typing. Cash at end March £10.7m. Cash at end Sept £5.0m.
"Robust balance sheet, with net cash of £5.0 million; prudent management of costs and cashflow"
Cash at 31.03.20 £10.7m. Cash at 30.09.20 £5.0m.
Cash burn from Ops £5.0m pa.
Crikey.
After the year we have had this is a really pleasijg summary of Financials.
First full year of revenue
· Strong momentum in sales and Annual Recurring Revenue (ARR) run rate across all its subscription-based software products
· Revenues of £0.6m, includes first revenue generated by Induction Switch (as previously indicated)
· Robust balance sheet, with net cash of £5.0 million; prudent management of costs and cashflow
· Deferred revenue at £0.6m (H1 2020: nil)
The Induction Switch App has some solid user reviews. INHC is not just about his app though, it seems like Board are building up a portfolio of channels and apps.
I agree with Khun that this is under the radar, possibly at the behest of the Board as it seems they want to be going about their business without much attention right now.
I think MicroGuide is the only revenue generating product at the moment. Induction Switch was added to NHSX recently so it may start to generate some revenue but would not imagine it to be too much right now.
If Board is to be believed, Switch App has proliferated through NHS staff. However these users are not paying for use. Question for INHC is how can this App (and others) be monetised? Will it be user subscription? Will it be institutional procurement? Perhaps an advertising model (unlikely in my opinion)? Or a combination of these ideas and/or others.
For those who want to get into INHC, my feeling is this will be a long term hold. Find an agreeable price to buy in (currently INHC trading at roughly 30% discount to its IPO price 18 months ago) and then forget about it for a couple years while platforms are developed and new channels are acquired.
Some big buys yesterday potential news on the way
Just read the RNS released yesterday, never a fan of none financial earn out targets, and even less of a fan of deferred consideration being paid out in cash! Take a look at The Panoply to see how it should be done... Very disappointing newsflow & performance since IPO.
"Since acquisition, Horizon's platform MicroGuide has grown revenue and delivered +32.0% YoY growth in registered users and +44% YoY growth in guideline page views as at 27 August 2020.
As part of the purchase agreement and as a result of Horizon achieving its earn-out target, a deferred contingent consideration of £1.5 million will be paid in cash."
Somebody loaded up big time after the bell yesterday.... 114k Worth....
Yeah agree I am tempted to buy some and prob will
Do . This has to be the future right and NHS needs to modernise . Shame I don’t know any healthcare workers who use the apps but reviews are very good . Feels like a high risk share though . Can they make money? It is not that clear to me . Reckon it’s a punt long term hold
I think it's very much under the radar but given it's already in key Hospitals and only listed for a year shows me the potential is very much ahead. Founders with solid track record and some key investors such as Dermot Desmond tells me well worth having a look at it. Potential is very good and with all the recent Covid impact then fully expect solid growth.This has long been overdue for the Health centre.
https://www.proactiveinvestors.co.uk/companies/news/920159/induction-healthcare-to-acquire-zesty-limited-as-it-builds-out-platform-for-medical-professionals-920159.html
Watching the video I found useful . Adding premium features to app . Charging hospitals I think
I am looking at this share as a possible investment BUT what I do not understand is what drives the revenue? Is the App itself licenced on payable basis? Or does the hospital buy the overall capability and pay for unlimited user licences?
I am trying to understand how the revenue will scale upwards over time with more users/hospitals using